Invokana Wins, Top-ranked Hospitals for Cancer, and the Rest of the News

The use of canagliflozin (INVOKANA, Janssen Pharmaceuticals) reduces the risk of both renal failure and cardiovascular events, according to a clinical trial published in The New England Journal of Medicine and presented at the International Society of Nephrology’s World Congress of Nephrology.

In other kidney related news, preoperative anemia had no negative impact on kidney function following laparoscopic bariatric surgery, according to researchers of a study published in Obesity Surgery.

A study published in European Radiology indicates that pre-existing renal function impairment was not associated with acute kidney injury (AKI) in patients exposed to iodinated contrast material (ICM).

In oncology news, cancer patients who undergo complex surgery at top-ranked cancer hospitals stand a much lower risk of mortality than patients who have complex surgeries at their affiliates, according to a study published in JAMA.

Furthermore, researchers found no discernible difference in Medicare spending on prostate cancer care based on provider Accountable Care Organization affiliation, according to the findings of a Prostate Cancer and Prostatic Diseases published study.

In neurology news, dopaminergic neuroimaging was indicated as a potentially useful biomarker of Parkinson’s disease severity, according to a study published in American Journal of Roentgenology.

Another study, published in PLoS One, suggests an association between heavy smoking and the gene OPRM1 when mental illness and dental clinical data were used as covariates.